JHVEPhoto/iStock Editorial via Getty Images
Ahead of a conference call with investment analysts on Tuesday, Pfizer (PFE) reaffirmed its 2025 outlook for adjusted earnings per share but revised its revenue outlook for the year to a level slightly below Street forecasts.
Pfizer (PFE) continues
